4DMT Announces Presentations at ARVO 2024 Annual Meeting
01 mai 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a...
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
28 mars 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of...
4DMT to Participate in Upcoming Investor Conferences
04 mars 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
29 févr. 2024 16h05 HE
|
4D Molecular Therapeutics, Inc.
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling...
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
12 févr. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of...
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
06 févr. 2024 23h27 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of...
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
05 févr. 2024 16h05 HE
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of...
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
03 févr. 2024 17h00 HE
|
4D Molecular Therapeutics, Inc.
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12...
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
29 janv. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and...
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
23 janv. 2024 08h00 HE
|
4D Molecular Therapeutics, Inc.
4D-710 has demonstrated promising, reproducible, CFTR expression significantly above normal levels for seven patients across Cohorts 1 & 2 (1E15-2E15 vg) and durable improvement or stabilization...